Cargando…

Model-Based Characterization of the Bidirectional Interaction Between Pharmacokinetics and Tumor Growth Dynamics in Patients with Metastatic Merkel Cell Carcinoma Treated with Avelumab

PURPOSE: Empirical time-varying clearance models have been reported for several immune checkpoint inhibitors, including avelumab (anti–programmed death ligand 1). To investigate the exposure-response relationship for avelumab, we explored semimechanistic pharmacokinetic (PK)–tumor growth dynamics (T...

Descripción completa

Detalles Bibliográficos
Autores principales: Grisic, Ana-Marija, Xiong, Wenyuan, Tanneau, Lénaïg, Jönsson, Siv, Friberg, Lena E., Karlsson, Mats O., Dai, Haiqing, Zheng, Jenny, Girard, Pascal, Khandelwal, Akash
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9365383/
https://www.ncbi.nlm.nih.gov/pubmed/34921021
http://dx.doi.org/10.1158/1078-0432.CCR-21-2662
_version_ 1784765333176844288
author Grisic, Ana-Marija
Xiong, Wenyuan
Tanneau, Lénaïg
Jönsson, Siv
Friberg, Lena E.
Karlsson, Mats O.
Dai, Haiqing
Zheng, Jenny
Girard, Pascal
Khandelwal, Akash
author_facet Grisic, Ana-Marija
Xiong, Wenyuan
Tanneau, Lénaïg
Jönsson, Siv
Friberg, Lena E.
Karlsson, Mats O.
Dai, Haiqing
Zheng, Jenny
Girard, Pascal
Khandelwal, Akash
author_sort Grisic, Ana-Marija
collection PubMed
description PURPOSE: Empirical time-varying clearance models have been reported for several immune checkpoint inhibitors, including avelumab (anti–programmed death ligand 1). To investigate the exposure-response relationship for avelumab, we explored semimechanistic pharmacokinetic (PK)–tumor growth dynamics (TGD) models. PATIENTS AND METHODS: Plasma PK data were pooled from three phase I and II trials (JAVELIN Merkel 200, JAVELIN Solid Tumor, and JAVELIN Solid Tumor JPN); tumor size (TS) data were collected from patients with metastatic Merkel cell carcinoma (mMCC) enrolled in JAVELIN Merkel 200. A PK model was developed first, followed by TGD modeling to investigate interactions between avelumab exposure and TGD. A PK-TGD feedback loop was evaluated with simultaneous fitting of the PK and TGD models. RESULTS: In total, 1,835 PK observations and 338 TS observations were collected from 147 patients. In the final PK-TGD model, which included the bidirectional relationship between PK and TGD, avelumab PK was described by a two-compartment model with a positive association between clearance and longitudinal TS, with no additional empirical time-varying clearance identified. TGD was described by first-order tumor growth/shrinkage rates, with the tumor shrinkage rate decreasing exponentially over time; the exponential time-decay constant decreased with increasing drug concentration, representing the treatment effect through tumor shrinkage inhibition. CONCLUSIONS: We developed a TGD model that mechanistically captures the prevention of loss of antitumor immunity (i.e., T-cell suppression in the tumor microenvironment) by avelumab, and a bidirectional interaction between PK and TGD in patients with mMCC treated with avelumab, thus mechanistically describing previously reported time variance of avelumab elimination.
format Online
Article
Text
id pubmed-9365383
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher American Association for Cancer Research
record_format MEDLINE/PubMed
spelling pubmed-93653832023-01-05 Model-Based Characterization of the Bidirectional Interaction Between Pharmacokinetics and Tumor Growth Dynamics in Patients with Metastatic Merkel Cell Carcinoma Treated with Avelumab Grisic, Ana-Marija Xiong, Wenyuan Tanneau, Lénaïg Jönsson, Siv Friberg, Lena E. Karlsson, Mats O. Dai, Haiqing Zheng, Jenny Girard, Pascal Khandelwal, Akash Clin Cancer Res Clinical Trials: Immunotherapy PURPOSE: Empirical time-varying clearance models have been reported for several immune checkpoint inhibitors, including avelumab (anti–programmed death ligand 1). To investigate the exposure-response relationship for avelumab, we explored semimechanistic pharmacokinetic (PK)–tumor growth dynamics (TGD) models. PATIENTS AND METHODS: Plasma PK data were pooled from three phase I and II trials (JAVELIN Merkel 200, JAVELIN Solid Tumor, and JAVELIN Solid Tumor JPN); tumor size (TS) data were collected from patients with metastatic Merkel cell carcinoma (mMCC) enrolled in JAVELIN Merkel 200. A PK model was developed first, followed by TGD modeling to investigate interactions between avelumab exposure and TGD. A PK-TGD feedback loop was evaluated with simultaneous fitting of the PK and TGD models. RESULTS: In total, 1,835 PK observations and 338 TS observations were collected from 147 patients. In the final PK-TGD model, which included the bidirectional relationship between PK and TGD, avelumab PK was described by a two-compartment model with a positive association between clearance and longitudinal TS, with no additional empirical time-varying clearance identified. TGD was described by first-order tumor growth/shrinkage rates, with the tumor shrinkage rate decreasing exponentially over time; the exponential time-decay constant decreased with increasing drug concentration, representing the treatment effect through tumor shrinkage inhibition. CONCLUSIONS: We developed a TGD model that mechanistically captures the prevention of loss of antitumor immunity (i.e., T-cell suppression in the tumor microenvironment) by avelumab, and a bidirectional interaction between PK and TGD in patients with mMCC treated with avelumab, thus mechanistically describing previously reported time variance of avelumab elimination. American Association for Cancer Research 2022-04-01 2021-12-16 /pmc/articles/PMC9365383/ /pubmed/34921021 http://dx.doi.org/10.1158/1078-0432.CCR-21-2662 Text en ©2021 The Authors; Published by the American Association for Cancer Research https://creativecommons.org/licenses/by-nc-nd/4.0/This open access article is distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) license.
spellingShingle Clinical Trials: Immunotherapy
Grisic, Ana-Marija
Xiong, Wenyuan
Tanneau, Lénaïg
Jönsson, Siv
Friberg, Lena E.
Karlsson, Mats O.
Dai, Haiqing
Zheng, Jenny
Girard, Pascal
Khandelwal, Akash
Model-Based Characterization of the Bidirectional Interaction Between Pharmacokinetics and Tumor Growth Dynamics in Patients with Metastatic Merkel Cell Carcinoma Treated with Avelumab
title Model-Based Characterization of the Bidirectional Interaction Between Pharmacokinetics and Tumor Growth Dynamics in Patients with Metastatic Merkel Cell Carcinoma Treated with Avelumab
title_full Model-Based Characterization of the Bidirectional Interaction Between Pharmacokinetics and Tumor Growth Dynamics in Patients with Metastatic Merkel Cell Carcinoma Treated with Avelumab
title_fullStr Model-Based Characterization of the Bidirectional Interaction Between Pharmacokinetics and Tumor Growth Dynamics in Patients with Metastatic Merkel Cell Carcinoma Treated with Avelumab
title_full_unstemmed Model-Based Characterization of the Bidirectional Interaction Between Pharmacokinetics and Tumor Growth Dynamics in Patients with Metastatic Merkel Cell Carcinoma Treated with Avelumab
title_short Model-Based Characterization of the Bidirectional Interaction Between Pharmacokinetics and Tumor Growth Dynamics in Patients with Metastatic Merkel Cell Carcinoma Treated with Avelumab
title_sort model-based characterization of the bidirectional interaction between pharmacokinetics and tumor growth dynamics in patients with metastatic merkel cell carcinoma treated with avelumab
topic Clinical Trials: Immunotherapy
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9365383/
https://www.ncbi.nlm.nih.gov/pubmed/34921021
http://dx.doi.org/10.1158/1078-0432.CCR-21-2662
work_keys_str_mv AT grisicanamarija modelbasedcharacterizationofthebidirectionalinteractionbetweenpharmacokineticsandtumorgrowthdynamicsinpatientswithmetastaticmerkelcellcarcinomatreatedwithavelumab
AT xiongwenyuan modelbasedcharacterizationofthebidirectionalinteractionbetweenpharmacokineticsandtumorgrowthdynamicsinpatientswithmetastaticmerkelcellcarcinomatreatedwithavelumab
AT tanneaulenaig modelbasedcharacterizationofthebidirectionalinteractionbetweenpharmacokineticsandtumorgrowthdynamicsinpatientswithmetastaticmerkelcellcarcinomatreatedwithavelumab
AT jonssonsiv modelbasedcharacterizationofthebidirectionalinteractionbetweenpharmacokineticsandtumorgrowthdynamicsinpatientswithmetastaticmerkelcellcarcinomatreatedwithavelumab
AT friberglenae modelbasedcharacterizationofthebidirectionalinteractionbetweenpharmacokineticsandtumorgrowthdynamicsinpatientswithmetastaticmerkelcellcarcinomatreatedwithavelumab
AT karlssonmatso modelbasedcharacterizationofthebidirectionalinteractionbetweenpharmacokineticsandtumorgrowthdynamicsinpatientswithmetastaticmerkelcellcarcinomatreatedwithavelumab
AT daihaiqing modelbasedcharacterizationofthebidirectionalinteractionbetweenpharmacokineticsandtumorgrowthdynamicsinpatientswithmetastaticmerkelcellcarcinomatreatedwithavelumab
AT zhengjenny modelbasedcharacterizationofthebidirectionalinteractionbetweenpharmacokineticsandtumorgrowthdynamicsinpatientswithmetastaticmerkelcellcarcinomatreatedwithavelumab
AT girardpascal modelbasedcharacterizationofthebidirectionalinteractionbetweenpharmacokineticsandtumorgrowthdynamicsinpatientswithmetastaticmerkelcellcarcinomatreatedwithavelumab
AT khandelwalakash modelbasedcharacterizationofthebidirectionalinteractionbetweenpharmacokineticsandtumorgrowthdynamicsinpatientswithmetastaticmerkelcellcarcinomatreatedwithavelumab